During the 2025 Endpoints News Drug Discovery Day, BioDuro’s Chief Scientific Officer Dr. Subas Sakya joined a distinguished panel discussion alongside other industry leaders to share key insights on accelerating and streamlining the discovery of both small molecules and biologics. This conversation explored the critical transition from discovery to development—one of the most challenging phases in drug innovation.
Bridging the chasm between discovery and development: Insights from your partners' C-suite
Accelerating and streamlining the discovery of both small molecules and biologics is challenging. One of the toughest parts of that process is transitioning your most promising programs into the clinic — it's the time when innovators often feel alone and under pressure to prove efficacy before they run out of resources. But it needn’t be such a lonely journey. We have assembled three leading discovery and development partners to provide insights on how collaboration can help you reach your endpoints faster and more efficiently.
Home